{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:14:50Z","timestamp":1758046490176,"version":"3.44.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.pharma.2022.11.006","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T20:17:21Z","timestamp":1668197841000},"page":"552-567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Th\u00e9saurus d\u2019interventions pharmaceutiques associ\u00e9es aux prescriptions injustifi\u00e9es d\u2019inhibiteurs de la pompe \u00e0 protons"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5910-2288","authenticated-orcid":false,"given":"L.","family":"Veremme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Janoly-Dumenil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Charpiat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2022.11.006_bib0555","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002095.pub4","article-title":"Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease","author":"van Pinxteren","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharma.2022.11.006_bib0560","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.2165\/00003495-200363240-00004","article-title":"Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know","volume":"63","author":"Robinson","year":"2003","journal-title":"Drugs"},{"unstructured":"Pallarito K. How safe are popular reflux drugs? Experts debate evidence linking acid-blockers to possible bone, heart problems n.d.","key":"10.1016\/j.pharma.2022.11.006_bib0565"},{"key":"10.1016\/j.pharma.2022.11.006_bib0570","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00228-019-02810-1","article-title":"Use of proton pump inhibitors in adults in France: a nationwide drug utilization study","volume":"76","author":"Lassalle","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0575","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bmj.39406.449456.BE","article-title":"Overprescribing proton pump inhibitors","volume":"336","author":"Forgacs","year":"2008","journal-title":"BMJ"},{"year":"1989","author":"Vidal","series-title":"MOPRAL 20mg - R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit","key":"10.1016\/j.pharma.2022.11.006_bib0580"},{"year":"2022","author":"ANSM","series-title":"MOPRAL 20mg, g\u00e9lule gastro-r\u00e9sistante - R\u00e9sum\u00e9 des caract\u00e9ristiques du produit","key":"10.1016\/j.pharma.2022.11.006_bib0585"},{"key":"10.1016\/j.pharma.2022.11.006_bib0590","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/pharmacy4040035","article-title":"Irrational use of medicines\u2014a summary of key concepts","volume":"4","author":"Ofori-Asenso","year":"2016","journal-title":"Pharmacy"},{"year":"2011","author":"Holloway","series-title":"The World Medicines Situation in 2011. Rational use of medicines","key":"10.1016\/j.pharma.2022.11.006_bib0595"},{"key":"10.1016\/j.pharma.2022.11.006_bib0600","article-title":"Time to halt the overprescribing of proton pump inhibitors","author":"Marks","year":"2016","journal-title":"Clin Pharm"},{"key":"10.1016\/j.pharma.2022.11.006_bib0605","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11845-018-1891-1","article-title":"Irrational use of proton pump inhibitors in general practise","volume":"188","author":"Ali","year":"2019","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.pharma.2022.11.006_bib0610","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40265-019-01110-3","article-title":"The clinician's guide to proton pump inhibitor related adverse events","volume":"79","author":"Elias","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.pharma.2022.11.006_bib0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2012.09.016","article-title":"Effets ind\u00e9sirables \u00e9mergents des inhibiteurs de la pompe \u00e0 protons [Emergent adverse effects of proton pump inhibitors]","volume":"42","author":"Bourne","year":"2013","journal-title":"Presse Med"},{"key":"10.1016\/j.pharma.2022.11.006_bib0620","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1007\/s11096-019-00929-w","article-title":"Snapshot of proton pump inhibitors prescriptions in a tertiary care hospital in Switzerland: less is more?","volume":"41","author":"Lenoir","year":"2019","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.pharma.2022.11.006_bib0625","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11096-019-00955-8","article-title":"The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study","volume":"42","author":"Sattayalertyanyong","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.pharma.2022.11.006_bib0630","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1742-1241.2012.02973.x","article-title":"Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care","volume":"66","author":"Ahrens","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.pharma.2022.11.006_bib0635","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/SMJ.0b013e31828db01f","article-title":"Four-year trends of inappropriate proton pump inhibitor use after hospital discharge","volume":"106","author":"Leri","year":"2013","journal-title":"South Med J"},{"key":"10.1016\/j.pharma.2022.11.006_bib0640","first-page":"652","article-title":"Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care","volume":"107","author":"Villama\u00f1\u00e1n","year":"2015","journal-title":"Rev Espanola Enfermedades Dig Organo Of Soc Espanola Patol Dig"},{"year":"2009","series-title":"Bon usage du m\u00e9dicament\u00a0: les inhibiteurs de la pompe \u00e0 protons chez l\u2019adulte [Appropriate Drug Use: Proton pump inhibitors in, adults]","key":"10.1016\/j.pharma.2022.11.006_bib0645"},{"year":"2019","series-title":"Am\u00e9liorer la qualit\u00e9 du syst\u00e8me de sant\u00e9 et ma\u00eetriser les, d\u00e9penses. Propositions de l\u2019Assurance maladie pour 2020","key":"10.1016\/j.pharma.2022.11.006_bib0650"},{"year":"2020","series-title":"Rapport d\u2019\u00e9valuation des inhibiteurs de la pompe \u00e0 protons (sp\u00e9cialit\u00e9s et g\u00e9n\u00e9riques)","key":"10.1016\/j.pharma.2022.11.006_bib0655"},{"year":"2020","series-title":"Note de cadrage. Fiche de bon usage du m\u00e9dicament \u00ab\u00a0Bon usage des inhibiteurs de la pompe \u00e0 protons\u00a0\u00bb","key":"10.1016\/j.pharma.2022.11.006_bib0660"},{"key":"10.1016\/j.pharma.2022.11.006_bib0665","first-page":"20","article-title":"[Pharmacist\u2019s interventions on proton pump inhibitor prescriptions in a University Hospital]","volume":"2","author":"Skalli","year":"2015","journal-title":"J Pharm Belg"},{"key":"10.1016\/j.pharma.2022.11.006_bib0670","doi-asserted-by":"crossref","first-page":"689","DOI":"10.14309\/ajg.0000000000000558","article-title":"Physicians\u2019 perceptions of proton pump inhibitor risks and recommendations to discontinue: a national survey","volume":"115","author":"Kurlander","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0675","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11096-006-9027-5","article-title":"Validation of an instrument for the documentation of clinical pharmacists\u2019 interventions","volume":"28","author":"Allenet","year":"2006","journal-title":"Pharm World Sci"},{"year":"2020","author":"Agence nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9 (ANSM)","series-title":"Th\u00e9saurus des interactions m\u00e9dicamenteuses","key":"10.1016\/j.pharma.2022.11.006_bib0680"},{"key":"10.1016\/j.pharma.2022.11.006_bib0685","doi-asserted-by":"crossref","first-page":"l536","DOI":"10.1136\/bmj.l536","article-title":"Management of acute upper gastrointestinal bleeding","author":"Stanley","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.pharma.2022.11.006_bib0690","series-title":"Chapter 49 - Pharmacotherapy for Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease. Goodman Gilmans Pharmacol. Basis Ther","first-page":"909","author":"Brunton","year":"2018"},{"key":"10.1016\/j.pharma.2022.11.006_bib0695","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.gie.2017.05.018","article-title":"Hemorrhagic angiodysplasia of the digestive tract: pathogenesis, diagnosis, and management","volume":"86","author":"Becq","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.pharma.2022.11.006_bib0700","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/apt.12527","article-title":"Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management","volume":"39","author":"Sami","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharma.2022.11.006_bib0705","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/SLA.0b013e3181b9eca4","article-title":"The association between cholecystectomy and gastroesophageal reflux symptoms: a prospective controlled study","volume":"251","author":"Lin","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.pharma.2022.11.006_bib0710","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases\u2013A position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"Scarpignato","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.pharma.2022.11.006_bib0715","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2796.1994.tb00855.x","article-title":"Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy","volume":"236","author":"Conn","year":"1994","journal-title":"J Intern Med"},{"key":"10.1016\/j.pharma.2022.11.006_bib0720","first-page":"A5540","article-title":"[Concomitant use of proton pump inhibitors and systemic corticosteroids]","volume":"157","author":"Dorlo","year":"2013","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.pharma.2022.11.006_bib0725","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","article-title":"ACCF\/ACG\/AHA 2008\u00a0expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"118","author":"Bhatt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharma.2022.11.006_bib0730","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3748\/wjg.15.457","article-title":"Risk factors for colonic diverticular bleeding: a Westernized community based hospital study","volume":"15","author":"Jansen","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0735","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.dld.2015.03.022","article-title":"Consensus guidelines on severe acute pancreatitis","volume":"47","author":"Pezzilli","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.pharma.2022.11.006_bib0740","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/jgh.13394","article-title":"Asian consensus statements on endoscopic management of walled-off necrosis Part 1: Epidemiology, diagnosis, and treatment: Asian consensus on endoscopic management","volume":"31","author":"Isayama","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0745","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.pan.2020.08.009","article-title":"Acid suppression therapy, gastrointestinal bleeding and infection in acute pancreatitis\u2013An international cohort study","volume":"20","author":"Demcs\u00e1k","year":"2020","journal-title":"Pancreatology"},{"key":"10.1016\/j.pharma.2022.11.006_bib0750","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1053\/j.gastro.2018.01.032","article-title":"American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on\u00a0Initial Management of Acute Pancreatitis","volume":"154","author":"Crockett","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharma.2022.11.006_bib0755","first-page":"347","article-title":"ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998","volume":"56","author":"ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis","year":"1999","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.pharma.2022.11.006_bib0760","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.2146\/ajhp060393","article-title":"Stress ulcer prophylaxis in hospitalized patients not in intensive care units","volume":"64","author":"Grube","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.pharma.2022.11.006_bib0765","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejim.2016.10.007","article-title":"The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal","volume":"37","author":"Savarino","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pharma.2022.11.006_bib0770","article-title":"Gastroprotection in patients on antiplatelet and\/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)","author":"Abrignani","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pharma.2022.11.006_bib0775","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/1060028014559244","article-title":"Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review","volume":"49","author":"Lo","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pharma.2022.11.006_bib0780","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/hep.20593","article-title":"Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial","volume":"41","author":"Shaheen","year":"2005","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.pharma.2022.11.006_bib0785","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases\u2013A position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"for the SIF-AIGO-FIMMG Group, on behalf of the Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.pharma.2022.11.006_bib0790","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11894-010-0141-0","article-title":"Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium","volume":"12","author":"Ito","year":"2010","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.pharma.2022.11.006_bib0795","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1001\/jama.2013.280490","article-title":"Proton pump inhibitor and histamine 2\u00a0receptor antagonist use and vitamin B 12\u00a0deficiency","volume":"310","author":"Lam","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pharma.2022.11.006_bib0800","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/02813432.2010.493315","article-title":"Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents","volume":"28","author":"Teramura-Gr\u00f6nblad","year":"2010","journal-title":"Scand J Prim Health Care"},{"key":"10.1016\/j.pharma.2022.11.006_bib0805","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.3390\/ijms20236031","article-title":"The phylogeny and biological function of gastric juice\u2014microbiological consequences of removing gastric acid","volume":"20","author":"Martinsen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2022.11.006_bib0810","doi-asserted-by":"crossref","first-page":"e1916205","DOI":"10.1001\/jamanetworkopen.2019.16205","article-title":"Association between acute gastroenteritis and continuous use of proton pump inhibitors during winter periods of highest circulation of enteric viruses","volume":"2","author":"Vilcu","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pharma.2022.11.006_bib0815","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pharma.2022.11.006_bib0820","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.amjmed.2011.01.007","article-title":"Proton pump inhibitors and risk of fractures: a meta-analysis of 11\u00a0international studies","volume":"124","author":"Yu","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.pharma.2022.11.006_bib0825","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.bone.2010.12.015","article-title":"Meta-analysis: risk of fractures with acid-suppressing medication","volume":"48","author":"Kwok","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.pharma.2022.11.006_bib0830","doi-asserted-by":"crossref","first-page":"8902367","DOI":"10.1155\/2021\/8902367","article-title":"Proton pump inhibitors and fractures in adults: a critical appraisal and review of the literature","volume":"2021","author":"Briganti","year":"2021","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0835","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.00015.2012","article-title":"Gastric acid, calcium absorption, and their impact on bone health","volume":"93","author":"Kopic","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharma.2022.11.006_bib0840","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2009.11.019","article-title":"A case series of proton pump inhibitor-induced hypomagnesemia","volume":"56","author":"Hoorn","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharma.2022.11.006_bib0845","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMc066308","article-title":"Proton-pump inhibitors and hypomagnesemic hypoparathyroidism","volume":"355","author":"Epstein","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2022.11.006_bib0850","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-151-10-200911170-00016","article-title":"Hypomagnesemia induced by several proton-pump inhibitors","volume":"151","author":"Broeren","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharma.2022.11.006_bib0855","first-page":"329","article-title":"Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole","volume":"68","author":"Fern\u00e1ndez-Fern\u00e1ndez","year":"2010","journal-title":"Neth J Med"},{"key":"10.1016\/j.pharma.2022.11.006_bib0860","first-page":"169","article-title":"Hypomagnesaemia due to use of proton pump inhibitors--a review","volume":"67","author":"Kuipers","year":"2009","journal-title":"Neth J Med"},{"key":"10.1016\/j.pharma.2022.11.006_bib0865","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2265.2008.03194.x","article-title":"Severe hypomagnesaemia in long-term users of proton-pump inhibitors","volume":"69","author":"Cundy","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"year":"2019","author":"Food and Drug Administration","series-title":"FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs)","key":"10.1016\/j.pharma.2022.11.006_bib0870"},{"key":"10.1016\/j.pharma.2022.11.006_bib0875","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1007\/s10620-012-2520-x","article-title":"Acid suppression therapy as a risk factor for candida esophagitis","volume":"58","author":"Kim","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.pharma.2022.11.006_bib0880","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.surg.2014.06.074","article-title":"Proton pump inhibitors induce changes in colonocyte gene expression that may affect Clostridium difficile infection","volume":"156","author":"Hegarty","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.pharma.2022.11.006_bib0885","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5009\/gnl.2014.8.1.41","article-title":"The simple predictors of pseudomembranous colitis in patients with hospital-acquired diarrhea: a prospective observational study","volume":"8","author":"Yang","year":"2014","journal-title":"Gut Liver"},{"key":"10.1016\/j.pharma.2022.11.006_bib0890","doi-asserted-by":"crossref","first-page":"e98400","DOI":"10.1371\/journal.pone.0098400","article-title":"Risk factors for recurrence, complications and mortality in clostridium difficile infection: a systematic review","volume":"9","author":"Abou Chakra","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pharma.2022.11.006_bib0895","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cgh.2009.12.022","article-title":"Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy","volume":"8","author":"Lombardo","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"year":"2012","author":"Food and Drug Administration","series-title":"FDA Drug Safety Communication: Clostridium difficile associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs)","key":"10.1016\/j.pharma.2022.11.006_bib0900"},{"key":"10.1016\/j.pharma.2022.11.006_bib0905","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1857","article-title":"Proton-pump inhibitor use and the risk of community-associated Clostridium difficile infection","author":"Inghammar","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharma.2022.11.006_bib0910","first-page":"1","article-title":"Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients","author":"Hazzan","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0915","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1086\/345435","article-title":"Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy","volume":"36","author":"Cordonnier","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharma.2022.11.006_bib0920","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3748\/wjg.v25.i8.888","article-title":"Current and future pharmacological therapies for managing cirrhosis and its complications","volume":"25","author":"Kockerling","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0925","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4254\/wjh.v11.i6.522","article-title":"Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients","volume":"11","author":"Fasullo","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0930","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3748\/wjg.v25.i21.2675","article-title":"Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis","volume":"25","author":"Ma","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0935","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jgh.12065","article-title":"Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis: acid-suppressive therapy and SBP","volume":"28","author":"Deshpande","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0940","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193890","article-title":"Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies","volume":"40","author":"Wu","year":"2020","journal-title":"Biosci Rep"},{"key":"10.1016\/j.pharma.2022.11.006_bib0945","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.3748\/wjg.v16.i46.5869","article-title":"PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis","volume":"16","author":"Garcia-Saenz-de-Sicilia","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0950","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/jgh3.12503","article-title":"Association between the chronic use of gastric acid suppressants and high-risk colorectal polyps","volume":"5","author":"Shiratori","year":"2021","journal-title":"JGH Open"},{"key":"10.1016\/j.pharma.2022.11.006_bib0955","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/apt.13203","article-title":"Proton pump inhibitor use significantly increases the risk of cryptogenic liver abscess: a population-based study","volume":"41","author":"Wang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharma.2022.11.006_bib0960","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00228-017-2256-9","article-title":"Correlation between proton pump inhibitors and risk of pyogenic liver abscess","volume":"73","author":"Lin","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0965","doi-asserted-by":"crossref","first-page":"184","DOI":"10.14740\/gr1404","article-title":"Is the use of proton pump inhibitors a predisposing factor for pyogenic liver abscesses?","volume":"14","author":"Elfiky","year":"2021","journal-title":"Gastroenterol Res"},{"key":"10.1016\/j.pharma.2022.11.006_bib0970","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.14512","article-title":"Treatment with proton pump inhibitors is associated with increased mortality in patients with pyogenic liver abscess","volume":"47","author":"Bettinger","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharma.2022.11.006_bib0975","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1071\/HI12039","article-title":"The combined use of proton pump inhibitors and antibiotics as risk factors for Clostridium difficile infection","volume":"18","author":"Kassavin","year":"2013","journal-title":"Healthc Infect"},{"key":"10.1016\/j.pharma.2022.11.006_bib0980","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/10245332.2016.1142711","article-title":"Association of proton pump inhibitors with the occurrence of gut-derived bacteraemia in patients with haematological malignancy after chemotherapy","volume":"21","author":"Zhou","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.pharma.2022.11.006_bib0985","first-page":"257","article-title":"Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients","volume":"15","author":"Sun","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.pharma.2022.11.006_bib0990","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1177\/1078155218818237","article-title":"Evaluation of the clinical impact of concomitant acid suppression therapy in colorectal cancer patients treated with capecitabine monotherapy","volume":"25","author":"Rhinehart","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.pharma.2022.11.006_bib0995","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamaoncol.2016.3358","article-title":"Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013\/LOGiC randomized clinical trial","volume":"3","author":"Chu","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pharma.2022.11.006_bib1000","series-title":"Abdom. Sepsis","first-page":"65","article-title":"Acute cholangitis","author":"Wang","year":"2018"},{"key":"10.1016\/j.pharma.2022.11.006_bib1005","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/apt.12694","article-title":"The use of proton pump inhibitors and the spectrum and number of biliary pathogens in patients with acute cholangitis","volume":"39","author":"Schneider","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharma.2022.11.006_bib1010","doi-asserted-by":"crossref","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1\u00a0checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pharma.2022.11.006_bib1015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1\u00a0immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pharma.2022.11.006_bib1020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti\u2013PD-1\u00a0efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pharma.2022.11.006_bib1025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pharma.2022.11.006_bib1030","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","article-title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials","volume":"31","author":"Chalabi","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharma.2022.11.006_bib1035","article-title":"Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150","author":"Hopkins","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharma.2022.11.006_bib1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvir.2020.12.020","article-title":"Proton pump inhibitors increase the risk of early biliary infection after placement of percutaneous transhepatic biliary stents","author":"Xu","year":"2021","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.pharma.2022.11.006_bib1045","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1177\/2050640618795928","article-title":"Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS)","volume":"6","author":"Sturm","year":"2018","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.pharma.2022.11.006_bib1050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jvir.2018.10.015","article-title":"Proton pump inhibitor use is associated with an increased frequency of new or worsening hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation","volume":"30","author":"Lewis","year":"2019","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"10.1016\/j.pharma.2022.11.006_bib1055","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.mayocp.2014.07.015","article-title":"Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine","volume":"89","author":"Marlicz","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pharma.2022.11.006_bib1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2015.10.022","article-title":"Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug\u2013induced small bowel injury: a randomized, placebo-controlled trial","volume":"14","author":"Washio","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pharma.2022.11.006_bib1065","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.dld.2012.12.005","article-title":"Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage","volume":"45","author":"Watanabe","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.pharma.2022.11.006_bib1070","doi-asserted-by":"crossref","first-page":"17490","DOI":"10.1038\/s41598-019-53559-7","article-title":"Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii","volume":"9","author":"Nadatani","year":"2019","journal-title":"Sci Rep"},{"year":"2010","author":"Food and Drug Administration","series-title":"FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors","key":"10.1016\/j.pharma.2022.11.006_bib1075"},{"key":"10.1016\/j.pharma.2022.11.006_bib1080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00280-018-3758-6","article-title":"Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction?","volume":"83","author":"Abu-Amna","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pharma.2022.11.006_bib1085","first-page":"354","article-title":"Deprescribing proton pump inhibitors: evidence-based clinical practice guideline","volume":"63","author":"Farrell","year":"2017","journal-title":"Can Fam Physician Med Fam Can"},{"key":"10.1016\/j.pharma.2022.11.006_bib1090","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/fampra\/cmu050","article-title":"Strategies for discontinuation of proton pump inhibitors: a systematic review","volume":"31","author":"Haastrup","year":"2014","journal-title":"Fam Pract"},{"key":"10.1016\/j.pharma.2022.11.006_bib1095","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/00365521.2012.746395","article-title":"Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment","volume":"48","author":"L\u00f8drup","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.pharma.2022.11.006_bib0550","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/00365520903477348","article-title":"Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint","volume":"45","author":"Waldum","year":"2010","journal-title":"Scand J Gastroenterol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:36:43Z","timestamp":1757720203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450922001493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0003450922001493"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.006","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Th\u00e9saurus d\u2019interventions pharmaceutiques associ\u00e9es aux prescriptions injustifi\u00e9es d\u2019inhibiteurs de la pompe \u00e0 protons","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}